Browsing Tag
remestemcel-L
1 post
Mesoblast (ASX: MSB) ramps up GVHD play with record Ryoncil revenue and fresh $125m credit line
Ryoncil sales surged 60 percent for Mesoblast in Q4. Read how its $125M refinancing plan could reshape capital efficiency and future cell therapy expansion.